Open Beta
MetriLume

US marketsRVMDW

SEC-sourced researchBeta

RVMDW

Revolution Medicines, Inc.

Company comparison ↗

Data passport

CIK
0001628171
Exchange
Nasdaq
Business activity
— · SIC 2836
Financial inputs
6/6
Filing date
Oct 1, 2026
SEC registry record
Operating company

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 11,580,000.0000 USD; December 2024: 0.0000 USD; December 2025: 0.0000 USD11.6M USD0 USD0December 2023December 2024December 2025
RVMDW · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202311,580,000.0000Feb 25, 2026
December 20240.0000Feb 25, 2026
December 20250.0000Feb 25, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20250.0000-1,131,301,000.0000-897,741,000.00002,354,508,000.0000723,211,000.0000Feb 25, 2026
December 20240.0000-600,093,000.0000-557,436,000.00002,558,301,000.0000293,097,000.0000Feb 25, 2026
December 202311,580,000.0000-436,367,000.0000-350,572,000.0000——Feb 25, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$0December 2025Feb 25, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$0December 2024Feb 25, 202610-K
Net incomeNetIncomeLoss-$1.13BDecember 2025Feb 25, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$897.74MDecember 2025Feb 25, 202610-K
Total assetsAssets$2.35BDecember 2025Feb 25, 202610-K
Total liabilitiesLiabilities$723.21MDecember 2025Feb 25, 202610-K

New filings

Explore methodology ↗